Metformin (fortamet, Glucophage, Glumetza, Riomet)
Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion News Brief for October 2017 [hide all summaries] (October 2017) In this month’s news brief, we report on the FDA’s recent decision to partially grant a petition from Public Citizen to require the addition of a warning about a dangerous drug-drug interaction to product labeling of repaglinide-containing diabetes medications. Drugs That Are Most Likely to Land Patients in the Emergency Room [hide all summaries] (June 2017) Many adverse drug reactions are severe enough to cause serious injury, hospitalization and even death. Find out which outpatient medications are most likely to cause adverse events that necessitate a visit to the emergency room. Type 2 Diabetes: A Guide to Prevention and Treatment [hide all summaries] (May 2014) The treatment options for Type 2 diabetes can be overwhelming. This article provides a comprehensive summary of our independent expert views on the best approaches for preventing and treating this common disease. Exenatide (BYDUREON) Injection to Control Blood Sugar in Type 2 Diabetes [hide all summaries] (May 2012) The article explains why you should not use the newly approved diabetes drug exenatide (BYDUREON), a long-acting dosage form of the previously approved BYETTA. Important safety concerns cited in the drug’s label and FDA warnings are also discussed. Bladder Cancer Warning for Pioglitazone (ACTOS) [hide all summaries] (November 2011) Find out the full list of serious problems with pioglitazone (ACTOS) that cause it to be a DO NOT USE drug, of which bladder cancer is but the latest. Review of Type-2 Diabetes Medication Liraglutide (VICTOZA) [hide all summaries] (April 2011) This article reviews the s Continue reading >>
Safety Alert: Glipizide With Metformin Hydrochloride, Glipizide With Metformin--corepharma, Llc Recalls Select Lots Of Glipizide And Metformin Tablets | Mediguard
This recall for Glipizide and Metformin 2.5 mg /250 mg, 2.5 mg/250 mg and 5 mg/500 mg tablets from CorePharma, LLC was issued at a warehouse/pharmacy level only. The FDA and the manufacturer have determined that any recalled product that may have been dispensed to patients does not pose a significant health risk. However, if you take Glipizide and Metformin tablets, you may wish to check your medicine - if you see any metal particles in your tablets, take your prescription to your pharmacist to examine. If you take Glipizide and Metformin tablets and have any other concerns or questions, you should follow up with your doctor. CorePharma, LLC Recalls Select Lots of Glipizide and Metformin Tablets CorePharma, LLC is recalling several lots of Glipizide and Metformin 2.5 mg /250 mg, 2.5 mg/500 mg and 5 mg/500 mg tablets because it is possible that the tablets contain tiny pieces of metal. The following lot numbers have been recalled: 1) Glipizide and Metformin Tablets 2.5 mg/250 mg - Lot numbers 100606 and 102466 2) Glipizide and Metformin Tablets 2.5 mg/500 mg - Lot numbers CPI870, CPB931, 100387, 100824, 101101, 101651, 102482, and 102483 3) Glipizde and Metformin Tablets 5 mg/500 mg - Lot numbers CPK825, CPB914, CPB915, 100353, 100354, 100573, 100602, 100939, 101096, 101097, 101652, 101653, 102484, 102486, and 102485 Glipizide and Metformin tablets are used in the treatment of diabetes. The combination of Glipizide and Metformin is also sold under the brand name Metaglip. This recall alert only applies to the select lots of the generic Glipizide and Metformin tablets made by CorePharma, LLC. No other lots, strengths, or brands were involved in this recall. To view the FDA notice about this recall, please visit: more information here Monitor the medical treatment of you Continue reading >>
Recall Of Merformin Extended Release Tablets Mg | Diabetic Connect
RECALL OF MERFORMIN EXTENDED RELEASE TABLETS 500 MG By imsuzie2 Latest Reply2010-08-10 05:58:16 -0500 Glumetza: Depomed Inc. Recalls Several Lots Depomed Inc. and Patheon Puerto Rico, Inc. have recalled select lots of Glumetza (metformin hydrochloride) Extended Release Tablets, 500 mg because of chemical contamination with TBA (2,4,6 tribomoanisole). This chemical is the same chemical that caused a musty and moldy odor in the recent recall of Tylenol products. These recalled products come in physician samples given out at doctor visits and 100 count bottles which are dispensed by pharmacists in the specific amount prescribed. The following lot numbers have been recalled: Physician Samples: Lot numbers 09T4531A, 09T6651A, 09T6661A, 09T6671, 09T11511, 10T0631A, 10T1851A, 10T1861A, and 10T2621A Bottles of 100 Tablets: Lot numbers 09T4501A, 09T4511A, 09T4521A, 09T6681A, 09T6691A, 09T6681A, 09T6701A, 09T6711A, 09T7131A, 09T9091A, 09T9101A, 09T9111A, 09T9121A, 09T9131A9, 09T2151A, 09T2161A, 09T2141A, 09T2701A, 09T731A, 09T2741A, 09T2751A, 09T2771A, 09T2761A, 09T2781A, 09T3631A, 09T3641A, 09T3651A, 09T3661A, 09T4431A, 09T4421A, 09T4441A, 09T4451A, 09T4461A, 09T4471A, 09T4481A, 09T4491A, 09T9141A, 09T9151A, 09T9161A, 09T9171A, 09T9181A, 09T9191A, 09T9201A, 09T9211A, 09T9221A, 09T9231A, 09T9241A, 09T9251A, 09T9691A, 09T9701A, and 09T11521A Glumetza contains the active ingredient metformin and is used in the treatment of diabetes. Metformin is also sold under the brand name Glucophage and Glucophage XR. This recall alert only applies to the select lots of Glumetza Tablets, 500 mg. No other metformin products were involved in this recall. To view the FDA notice about this recall, please visit: This recall for Glumetza tablets 500 mg was issued at a warehouse and physician/pharmac Continue reading >>
Metformin Makes Headline News
Metformin is the first-line drug of choice in the treatment of type II diabetes. It was first approved in Europe in 1958.1 Americans had to wait until 1994 to legally obtain metformin.1 The holdup in approving metformin goes beyond the FDA. It is an indictment of a political/legal system that will forever cause needless suffering and death unless substantively changed. When Life Extension® informed Americans about drugs like metformin in the 1980s, the FDA did everything in its power to incarcerate me and shut down our Foundation.2 FDA propaganda at the time was that consumers needed to be "protected" against "unproven" therapies. As history has since proven, the result of the FDA's embargo has been unparalleled human carnage. So called "consumer protection" translated into ailing Americans being denied access to therapies that the FDA now claims are essential to saving lives. Today's major problem is not drugs available in other countries that Americans can't access. Instead, it is a political/legal system that suffocates medical innovation. Headline news stories earlier this year touted the anti-cancer effects of metformin, data that Foundation members were alerted to long ago.3 The problem is that it is illegal for metformin manufacturers to promote this drug to cancer patients or oncologists. It's also illegal to promote metformin to healthy people who want to reduce their risk of cancer, diabetes, vascular occlusion, and obesity. This fatal departure from reality continues unabated, as our dysfunctional political/legal system denies information about metformin that could spare countless numbers of lives. Type II diabetics suffer sharply higher rates of cancer4-7and vascular disease.8-11 The anti-diabetic drug metformin has been shown in numerous scientific studies Continue reading >>
Januvia Lawsuits | Recall Report
Januvia, and the similar drug Janumet, were developed by Merck & Co. to treat type 2 diabetes. Many pharmaceutical companies have gotten a type 2 diabetes drug on the market in the last decade. These drugs have the potential to be big money makers for the companies because of the increasing rate of diabetes in the U.S. Patients who have taken either of these drugs have reported serious complications and lawsuits have been started claiming that Merck did not adequately warn the public about those risks. Some people have suffered from pancreatitis, pancreatic cancer, and thyroid cancer while taking Januvia or Janumet. If you took either of these drugs and feel that you werent warned about the potential complications you ultimately experienced, you may be in a position to start your own Januvia lawsuit. Januvia is a drug designed to treat type 2 diabetes, a chronic illness associated with dangerously high blood sugar levels. When it is left untreated this type of diabetes can lead to serious complications that eventually become debilitating and life threatening. The U.S. Food and Drug Administration (FDA) approved Januvia in 2006 and Janumet in 2007 for treatment of type 2 diabetes along with lifestyle changes including a healthy diet, exercise, and weight loss. Januvia is the generic drug sitagliptin and Janumet is a combination of sitagliptin and another drug called metformin. Sitagliptin belongs to the class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. These are drugs that inhibit the protein DPP-4. The result of inhibiting it is an increase in insulin production, which regulates blood sugar, and a decrease in the amount of sugar released into the blood by the liver. Janumet attacks high blood sugar levels with two drugs. It contains sitagliptin as well a Continue reading >>
Metformin Recall - Post Script
Apotex and the TGA are advising of a recall of a batch of metformin Apotex, in consultation with the TGA, is warning consumers and health professionals that it is recalling a batch of APO-Metformin XR 1000 mg tablets (batch number E16539). There has been a report of a small piece of white plastic likely from a cable or zip tie embedded in a tablet from this batch. The plastic may or may not be visible, as it could be completely embedded in the tablet, Apotex and the TGA say. If a small piece of plastic is swallowed with the tablet there is a small risk of choking or perforation of the gastrointestinal tract. The plastic is not toxic or carcinogenic. They are advising patients and their carers to check the batch number on any packets of AJP-Metformin XR 1000mg to see whether it is from the affected batch, and to return any product from the affected batch to a pharmacy for refund or replacement. Apotex says it is writing to pharmacists to provide further information about the issue, including details of the recall procedure. It has asked them to inspect their stock and quarantine any from batch number E16539. If pharmacists or any other health professionals notice or receive reports of any suspected contamination of other batches of APO-Metformin XR 1000 mg tablets, please report it to the TGA, it says. For further information contact Apotex on 1800 276 839. Continue reading >>
Metformin Linked To Dementia, Parkinson's In Patients With T2dm
Metformin Use Linked to Increased Dementia, Parkinson's Risk in Patients With Diabetes VIENNA, Austria — Long-term use of the diabetes medication metformin may increase the risk for neurodegenerative disease in patients with type 2 diabetes mellitus (T2DM), new research suggests. In a cohort study that followed about 9300 patients with T2DM in Taiwan for up to 12 years, the risk for Parkinson's disease (PD) or Alzheimer's dementia was more than double during a 12-year period for those who took metformin vs those who did not — even after adjusting for multiple confounders. In addition, outcome risks increased progressively with higher dosage and longer duration of treatment. The results were presented here at AD/PD 2017: The 13th International Conference on Alzheimer's and Parkinson's Diseases by Yi-Chun Kuan, MD, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Interestingly, recent research has suggested that use of metformin may protect against neurodegenerative diseases. When asked about that, Dr Kuan told Medscape Medical News that "some studies have actually found positive [outcomes] but some have been negative ." So the researchers wanted to look into this using their own data. "We'd heard about a possible protective effect from metformin. However, we found the reverse," she said, but stressed that large-scale, prospective studies in other countries are needed to clarify the results. The investigators note that past research has shown a link between T2DM and increased risk for neurodegenerative diseases, but there's been "some question" about the association with specific diabetes medications. They examined records for patients with T2DM from the National Health Insurance research database of Taiwan, including 4651 who had metformin pre Continue reading >>
Sun Pharma Recalls Two Batches Of Diabetic Drug From Us Market - Business Line
Sun Pharma recalls two batches of diabetic drug from US market Sun Pharmaceutical Industries has started recalling two batches of Riomet (metformin hydrochloride) Oral Solution voluntarily from the US market due to microbial contamination. Riomet (metformin oral solution) is an oral diabetes medicine that helps control blood sugar level. According to a notification put up by the US Food and Drug Administration in its website, the recall was initiated by the firm under Class-II classification. The notification did not mention the quantity that is being recalled. The Riomet (Metformin Hydrochloride Oral Solution) has been found to be contaminated (with Scopulariopsis brevicaulis). The contamination was discovered during sample preparation for the Antimicrobial Preservative Effectiveness Testing (AMPET) being performed as part of the 12 month stability study interval, Sun Pharma informed the FDA in a letter. According to the USA health regulator, Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The drug was manufactured for Ranbaxy Laboratories Inc Jacksonville in USA by a contract manufacturer and distributed by Sun Pharmaceutical Industries subsidiary in Cranbury, New Jersey. The Sun Pharma stock closed at Rs 528.60 apiece on BSE, up 0.28 per cent over previous close. Continue reading >>
- Bernie Sanders sends another Big Pharma giant’s stock plummeting after diabetes drug Tweetstorm
- States investigate pharma companies, CVS Health as diabetes drug prices reach record highs
- Khloe Kardashian Recalls Emotional Rob Kardashian ''Intervention,'' Says She's Seen a ''Great Transformation'' Since Diabetes Diagnosis
Invokana® (canagliflozin) And Invokamet® (canagliflozin And Metformin) - Risk Of Lower Limb Amputation
Report a Concern Posting date: September 6, 2017 Type of communication: Dear Healthcare Professional Letter Subcategory: Drugs Source of recall: Health Canada Issue: Product Safety Audience: Healthcare Professionals, Hospitals Identification number: RA-64366 Audience Healthcare professionals including internal medicine specialists, endocrinologists, cardiologists, nephrologists, general or family practitioners, emergency healthcare professionals, critical care physicians, diabetic and homecare nurses, certified diabetes educators and pharmacists. Key messages An approximately two-fold increased risk of surgical lower limb amputation (primarily of the toe and midfoot but also of the leg) has been observed in two long-term clinical studies in type 2 diabetes patients with established cardiovascular disease (CVD) or at least two risk factors for CVD treated with INVOKANA. Healthcare professionals are advised to: consider factors in the patient history that may increase the risk for lower limb amputation before initiating INVOKANA or INVOKAMET. carefully monitor patients with a higher risk for amputation. counsel patients about the importance of routine preventative foot care and adequate hydration. discontinue INVOKANA or INVOKAMET treatment in patients who develop a significant complication which may precede amputation such as lower-extremity skin ulcer, infection, osteomyelitis or gangrene. The Canadian Product Monographs of INVOKANA and INVOKAMET will be updated to reflect this safety information. Issue What is the issue? An increase in the incidence rate of lower limb amputation-primarily of the toe and midfoot, but also of the leg has been seen in the integrated CANagliflozin cardioVascular Assessment Study (CANVAS) Program (0.63 per 100 patient-years in patients trea Continue reading >>
Safety Alert: Metformin--teva Pharmaceuticals Recalls Single Lot Of Metformin Hydrochloride Tablets, Usp 500 Mg | Mediguard
This recall for Metformin Hydrochloride Tablets, USP 500 mg from Teva Pharmaceuticals was issued at a warehouse and pharmacy level only. The FDA and the manufacturer have determined that any recalled product that may have been dispensed to patients does not pose a significant health risk. If you take Metformin Hydrochloride Tablets, USP 500 mg and are concerned, you should speak to your doctor. Teva Pharmaceuticals Recalls Single Lot of Metformin Hydrochloride Tablets, USP 500 mg Teva Pharmaceutical has recalled a single lot of Metformin Hydrochloride Tablets, USP 500 mg. Lot number 35201115A is being recalled because routine testing found that the hardness of the tablets did not meet the required level in samples from this lot. Metformin is used in the treatment of diabetes. Metformin is also sold under the brand name Glucophage. No other lots, strengths, or brands of metformin were involved in this recall. To view the FDA notice about this recall, please visit: more information here Monitor the medical treatment of you and your loved ones. DISCLAIMER: MediGuard is not intended to be a substitute for professional medical advice. MediGuard cannot and does not take into consideration every possible interaction or account for individual responses to medicine. Different individuals may respond to medication in different ways. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Always seek the advice of a qualified health provider with any questions you may have before making any changes to your treatment. The use of the MediGuard site and its content is at your own risk. The MediGuard site and the information contained in it is in Continue reading >>
Apotex Recalls Metformin Batch In Australia
Apotex recalls metformin batch in Australia Apotex has recalled a batch its diabetes drug APO-Metformin XR in Australia after a pill was plastic from a cable or zip tie was found embedded in a pill. The Therapeutic Goods Administration (TGA) posted details on its website on January 19, explaining that Apotex initiated the recall as a precautionary measure over concerns the pills pose a threat to patients. The TGA wrote, There has been one report of a small piece of white plastic likely from a cable/zip tie being embedded in a tablet from this batch. The plastic may or may not be visible, as it could be completely embedded in the tablet. If a small piece of plastic is swallowed with the tablet there is a small risk of choking or perforation of the gastrointestinal tract. The plastic is not toxic or carcinogenic. Copyright - Unless otherwise stated all contents of this web site are 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions Continue reading >>
Actos
Actos (pioglitazone) is an oral Type 2 diabetes drug that lowers blood sugar by decreasing insulin resistance and reducing the amount of glucose made in the liver. This allows the body to better dispose of excess blood sugar. Typically, the dose starts at 15 or 30 mg and is taken once a day, but some people may require a stronger dose. Doctors can increase the strength of the medicine by 15 mg increments to a maximum of 45 mg daily. However, numerous studies and a review by the U.S. Food and Drug Administration (FDA) link higher dosages and prolonged use to an increased risk of bladder cancer and other serious conditions. Actos is not intended to treat Type 1 diabetes or diabetic ketoacidosis. The drug can be used alone or with other Type 2 diabetes medicines such as metformin. There are two additional types of Actos that combine pioglitazone and metformin: Actoplus Met and Actoplus Met XR (extended release). What Does Actos Treat? Actos is approved to treat Type 2 diabetes in adults by improving glycemic (defined as causing glucose – sugar – in the blood) control. The drug comes in a tablet form to be taken by mouth daily and should be used in combination with diet and exercise. People with Type 2 diabetes do not make or use insulin well. Insulin is a hormone produced by the pancreas that regulates the amount of glucose in the blood. It moves blood sugar into cells where it is stored for later use as energy. Type 2 diabetes results in higher than normal levels of glucose because glucose does not enter cells. The body is then unable to use the glucose for energy. Type 2 diabetes is a lifelong (chronic) disease that can develop at any age, including during childhood. However, it mostly occurs in middle-aged and older people. The condition often develops slowly over t Continue reading >>
Diabetes Drug Recalled
Aurobindo Pharma Ltd. is recalling a single lot of metformin hydrochloride tablets, USP, 1000 mg, after a metformin BP 1000-mg tablet was found in a bottle. The recall was included in the February 28, 2018, US Food and Drug Administration (FDA) Enforcement Report. The recall affects 500-count bottles from lot MTSC17145-A, which has an expiration date of July 2021. Bottles from the lot were distributed across the United States. Aurobindo Pharma voluntarily initiated the recall February 2, 2018. On February 16, 2018, the FDA designated it Class III, suggesting use of the affected product is not likely to cause harm. Metformin is a prescription drug used to improve glycemic control in people with type 2 diabetes. For more Pharmacy Learning Network articles, visit the homepage To learn about Pharmacy Learning Network Live meetings, click here NEW YORK (Reuters Health) - Patients recovering from sepsis may face a significantly increased risk of heart attack or stroke in the first four weeks after discharge from the hospital, researchers in Taiwan say. "The outcome of sepsis has been greatly improved in the past decade after the implementation of evidence-based sepsis care bundles," Dr. Chein-Chang Lee from National Taiwan University told Reuters Health by email. "The integration of stroke and myocardial prevention after sepsis recovery into the sepsis care bundle may have the potential to further improve the outcome." Dr. Lee and colleagues studied more than one million patients in a national Taiwanese database from 2000-2010, including 42,316 who had sepsis. Patients were matched to a general population control group with similar characteristics and to a hospital control group of patients who did not develop sepsis. As reported online September 10 in CMAJ, within 180 days Continue reading >>
Apo-metformin Xr 1000 Mg Tablets
Australian Government Department of Health Recall - risk of injury due to potential contamination with plastic fragment Consumers and health professionals are advised that Apotex, in consultation with the TGA, is recalling one batch of APO-Metformin XR 1000 mg tablets (batch number E16539). APO-Metformin XR 1000 mg tablets are used to treat type 2 diabetes in adults and children over 10 years of age. There has been one report of a small piece of white plastic (likely from a cable/zip tie) being embedded in a tablet from this batch. The plastic may or may not be visible, as it could be completely embedded in the tablet. If a small piece of plastic is swallowed with the tablet there is a small risk of choking or perforation of the gastrointestinal tract. The plastic is not toxic or carcinogenic. No other batches are affected by this recall. If you or someone you provide care for takes APO-Metformin XR 1000 mg tablets, check the batch number on the package to see if it is from the affected batch (batch number E16539). If you have a product from the affected batch, return it to a pharmacy for a refund or replacement. If you have any other questions or concerns about this issue, talk to your health professional. If you treat patients who take APO-Metformin XR 1000 mg tablets, please be aware of this issue. Apotex is writing to pharmacists to provide further information about this issue, including details of the recall procedure. Please inspect your stock and quarantine any products from the affected batch (batch number E16539). Patients returning unused or partially used packs should be provided a full refund or replacement. If pharmacists or any other health professionals notice or receive reports of any suspected contamination of other batches of APO-Metformin XR 1000 mg Continue reading >>
Tga - Therapeutic Goods Administration (via Public) / Recall: Apo-metformin Xr 1000 Mg Tablets
01/19/2018 | Press release | Distributed by Public on 01/18/2018 23:02 Consumers and health professionals are advised that Apotex, in consultation with the TGA, is recallingone batch of APO-Metformin XR 1000 mg tablets (batch number E16539). APO-Metformin XR 1000 mg tablets are used to treat type 2 diabetes in adults and children over 10 years of age. There has been one report of a small piece of white plastic (likely from a cable/zip tie) being embedded in a tablet from this batch. The plastic may or may not be visible, as it could be completely embedded in the tablet. If a small piece of plastic is swallowed with the tablet there is a small risk of choking or perforation of the gastrointestinal tract. The plastic is not toxic or carcinogenic. No other batches are affected by this recall. If you or someone you provide care for takes APO-Metformin XR 1000 mg tablets, check the batch number on the package to see if it is from the affected batch (batch number E16539). If you have a product from the affected batch, return it to a pharmacy for a refund or replacement. If you have any other questions or concerns about this issue, talk to your health professional. If you treat patients who take APO-Metformin XR 1000 mg tablets, please be aware of this issue. Apotex is writing to pharmacists to provide further information about this issue, including details of the recall procedure. Please inspect your stock and quarantine any products from the affected batch (batch number E16539). Patients returning unused or partially used packs should be provided a full refund or replacement. If pharmacists or any other health professionals notice or receive reports of any suspected contamination of other batches of APO-Metformin XR 1000 mg tablets, please report it to the TGA (see the ' Re Continue reading >>
